Clinical Trials Browser

High Grade Serous Carcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma

Breast Neoplasms, Neoplasm Metastasis

Breast Neoplasms

Esophageal Neoplasms, Stomach Neoplasms

Breast Neoplasms

Rhabdomyosarcoma, Sarcoma, Ewing

Metastatic Castration-resistant Prostate Cancer

Advanced Solid Tumors

Radiation Injuries, Triple Negative Breast Neoplasms

Neoplasms, Unknown Primary

Hodgkin Disease, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Endometrial Neoplasms

Castration-Resistant Prostate Carcinoma

Ovarian Neoplasms

Glioma, Recurrence

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Transitional Cell, Lung Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

Prostatic Neoplasms

Endometrial Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms

Triple Negative Metastatic Breast Cancer

Clinical Trials

CAPRI

RADIOLA

KEYLYNK-009

RADIOSARP

Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

KEYLYNK-008

OlympiAD

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors

RadioPARP

CUPISCO

Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant

ENDOLA

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

OVAL-1

OLAGLI

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Study to Evaluate CCS1477 in Advanced Tumours

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

KEYLYNK-010

Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours